SB0029 - Right to Try Act

• Allows eligible terminal patients (those expected to die within 24 months) to access investigational drugs, biological products, and devices that have completed Phase I clinical trials but lack FDA approval.

• Defines "eligible patient" as someone with a terminal illness who has considered all FDA-approved treatment options, received physician recommendation, and provided informed written consent (or parent/guardian consent if minor).

• Permits manufacturers to provide investigational treatments to eligible patients either without charge or by requiring patients to pay manufacturing costs; does not mandate manufacturer participation.

• Allows accident and health insurers to voluntarily cover costs of investigational drugs, biological products, or devices; prohibits requiring coverage.

• Exempts nursing home residents using investigational treatments under the Right to Try Act from institutional review board requirements that normally apply to experimental research.

• Prohibits disciplinary action against physicians based solely on recommending or prescribing investigational drugs, biological products, or devices to eligible patients.